Who
Kiran Mazumdar-Shaw
Director
Company insider
Files Form 4 as: Director and 10% owner, Bicara Therapeutics.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 12 Sep 2024
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,475 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,475 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,746 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000,000 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —9,990,144 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,000,000 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,000,000 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code C | —4,327,365 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,080,775 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code C | —324,552 at $0.00 | filing |
| 16 Sep 2024filed 16 Sep 2024 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code C | —432,736 at $0.00 | filing |
| 12 Sep 2024filed 16 Sep 2024 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,746 at $0.00 | filing |
News
India must shift pharma industry from generics to innovation-led growth: Kiran Mazumdar-Shawindiagazette.com · 13 Oct 2026India must shift pharma industry from generics to innovation-led growth: Kiran Mazumdar-Shawaustraliannews.net · 13 Oct 2026India must shift pharma industry from generics to innovation-led growth: Kiran Mazumdar-Shawwebindia123.com · 13 Oct 2026India must shift pharma industry from generics to innovation-led growth: Kiran Mazumdar-Shawcambodiantimes.com · 13 Oct 2026India must shift pharma industry from generics to innovation-led growth: Kiran Mazumdar-Shawaninews.in · 13 Oct 2026Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-Shawindiatimes.com · 10 Oct 2026Kiran Mazumdar-Shaw has a career lesson from 3 Nobel prize winners as AI forces layoffs and changes jobs across the worldindiatimes.com · 22 Sep 2026Rs 8.3 lakh Fendi bag resembling 'Rs 500' Indian market designs: Why the luxury brand did not 'credit' Indian artisans, ask Harsh Goenka, Kiran Mazumdar-Shawindiatimes.com · 16 Sep 2026
10 headlines in the last 90 days name Kiran Mazumdar-Shaw; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.